Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

DGX

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

DGX

AI Research Report

Powered by Claude

Ready to analyze DGX

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

📅 Earnings in 7d (Apr 21)

Analyst Consensus

Buy
Based on 24 analysts
Period: 2026-04-01
13 Buy (54%)11 Hold (46%)0 Sell (0%)
Rating Distribution
Strong Buy
6
Buy
7
Hold
11
Sell
0
Strong Sell
0
Trend
2026-04
13/11/0
2026-03
13/11/0
2026-02
13/11/0
2026-01
12/12/0
Quest Diagnostics Inc

Quest Diagnostics Inc

Health Care·NEW YORK STOCK EXCHANGE, INC.·US·IPO 1996-12-17
  • Yahoo·4h ago

    Q4 Earnings Roundup: Quest (NYSE:DGX) And The Rest Of The Testing & Diagnostics Services Segment

    The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Quest (NYSE:DGX) and the rest of the testing & diagnostics services stocks fared in Q4.

  • Yahoo·7h ago

    Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth

    Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Yahoo·1d ago

    Drug Screening Market Research and Global Forecast Report 2025-2030: Opportunities Expand with Oral Fluid Adoption, Fingerprint-Based Workplace Testing and Emerging Market Growth

    The global drug screening market is poised to grow from USD 10.36 billion in 2025 to USD 21.29 billion by 2030, at a CAGR of 15.5%, driven by stricter regulations and increased testing across safety-sensitive sectors. As substance use rises globally, with over 316 million drug users in 2023, impairment risks on roads and workplaces escalate. Road traffic injuries linked to drug use cause 1.3 million deaths annually, mostly in low- and middle-income countries. In the US, marijuana positivity has

Yahoo·3d ago

3 Cash-Producing Stocks That Fall Short

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

  • SeekingAlpha·4d ago

    Dividend Champion, Contender, And Challenger Highlights: Week Of April 12

    A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list here.

  • Yahoo·4d ago

    Digi Power X amends equity sales program, could raise up to $75 million

    Digi Power X Inc (NASDAQ:DGXX, FRA:1NQ0, NEO:DGX) said it has entered into an amended and restated sales agreement with AGP/Alliance Global Partners, allowing the company to raise up to $75 million through an at-the-market equity program. The energy infrastructure company, which is pivoting...

  • Yahoo·5d ago

    Digi Power X Enters into Amended and Restated Sales Agreement

    MIAMI, FL / ACCESS Newswire / April 9, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(CboeCanada:DGX) (the "Company"), an innovative energy infrastructure company pivoting into AI data centers and GPU-as-a-Service, announces that it has entered into an amended ...

  • Benzinga·6d ago

    Evercore ISI Group Maintains In-Line on Quest Diagnostics, Lowers Price Target to $210

    Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics (NYSE:DGX) with a In-Line and lowers the price target from $220 to $210.

  • View all news →
  • NEW YORK STOCK EXCHANGE, INC.After-hours
    Quest Diagnostics Inc
    Health Care
    $194.16
    $1.25 (+0.65%)
    After-hrs · vs prev close $192.91
    Open
    $192.27
    Prev close
    $192.91
    Day range
    $191.16 – $194.26
    52W range
    $159.83 – $213.50
    Mkt cap
    $21.19B
    P/E
    21.4
    EPS
    $8.78
    Beta
    0.64

    Fundamentals

    Valuation
    Market Cap
    $21.19B
    P/E (TTM)
    21.38S&P avg ~22
    P/S (TTM)
    1.92S&P avg ~2.8
    P/B
    2.69S&P avg ~4.5
    P/FCF
    15.61S&P avg ~26
    EPS (TTM)
    $8.78
    Book/sh
    $65.18
    Cash/sh
    $3.82
    Profitability
    Gross Margin
    33.32%avg ~45%
    Operating Margin
    14.10%avg ~15%
    Net Margin
    8.99%avg ~12%
    ROE
    13.88%avg ~18%
    ROA
    6.18%avg ~7%
    ROI
    7.71%
    Payout Ratio
    35.58%
    FCF/sh
    —
    Growth & Health
    Rev Growth YoY
    11.78%
    Rev Growth 5Y
    3.18%
    EPS Growth YoY
    14.15%
    EPS Growth 5Y
    -3.56%
    Current Ratio
    —
    Quick Ratio
    0.80
    Debt/Equity
    —
    LT Debt/Eq
    —
    Trading & Dividends
    Beta
    0.64
    52W High
    $213.50
    52W Low
    $159.83
    Avg Vol (10D)
    808.9K
    Avg Vol (3M)
    957.4K
    Div Yield
    1.78%
    Div/sh (TTM)
    —
    Analyst
    Buy (24)
    Price Performance
    5D-1.98%
    MTD-1.57%
    3M+8.53%
    6M+8.12%
    YTD+11.17%
    1Y+17.74%

    Factor Grades

    View details →
    B-
    Overall score: 60/100
    B
    Valuation
    C
    Growth
    C+
    Profitability
    B-
    Momentum
    B-
    Financial Health

    Recent insider activity

    View all →
    • 4FORM 4
      12d ago
    • 4FORM 4
      Mar 11
    • 4FORM 4
      Mar 6
    • 4FORM 4
      Mar 6
    • 4FORM 4
      Mar 6